2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Genitourinary
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
69
Breast Neoplasms
52
Carcinoma, Non-Small-Cell Lung
28
Neoplasms
27
Myelodysplastic Syndromes
27
Advanced Solid Tumors
27
Advanced Solid Tumor
26
Prostatic Neoplasms
24
Stomach Neoplasms
19
Recurrence
18
Multiple Myeloma
18
Carcinoma, Hepatocellular
18
Neoplasm Metastasis
17
Ovarian Neoplasms
15
Lung Neoplasms
15
Pancreatic Neoplasms
14
Uterine Cervical Neoplasms
13
Solid Tumor
13
Sarcoma
13
Melanoma
13
Leukemia, Myelomonocytic, Chronic
13
Colorectal Neoplasms
11
Triple Negative Breast Neoplasms
10
Small Cell Lung Carcinoma
10
Lymphoma, Large B-Cell, Diffuse
10
Squamous Cell Carcinoma of Head and Neck
8
Myeloproliferative Disorders
8
Lymphoma, Non-Hodgkin
8
Esophageal Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Interventions
Oxaliplatin
271
Fluorouracil
268
Capecitabine
234
Leucovorin
209
Irinotecan
152
Radiotherapy
138
Bevacizumab
114
Cetuximab
82
Surgical Procedures, Operative
51
Folfox protocol
48
Neoadjuvant Therapy
45
Drug Therapy
43
Radiation
42
Chemotherapy, Adjuvant
34
Chemoradiotherapy
34
Panitumumab
27
Magnetic Resonance Spectroscopy
26
XELOX
25
Radiotherapy, Intensity-Modulated
23
Biopsy
20
Surveys and Questionnaires
18
Laparoscopy
18
Proctectomy
17
Floxuridine
17
Early Intervention, Educational
16
Nivolumab
15
Immunohistochemistry
15
Gene Expression Profiling
15
Gemcitabine
15
pembrolizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
Injections
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled
NCT02584400
2019-03-08
HX4 SD
Maastricht Radiation Oncology
Phase 2
Terminated
1 enrolled